<DOC>
	<DOCNO>NCT01723371</DOCNO>
	<brief_summary>This study determine safety feasibility use β-blocker ( case carvedilol ) treatment pediatric patient Left Heart Failure ( LHF ) child Pulmonary Arterial Hypertension ( PAH ) . Carvedilol affect nervous system , system highly activate response stress patient PAH . Each patient administer dosage carvedilol , accord weight . This dosage increase incrementally span study , patient responds well drug . The study determine whether potential adverse side effect carvedilol outweigh possible positive result reduce LHF . The hypothesis study predict carvedilol positive effect treat LHF , similar use treatment Right Heart Failure ( RHF ) . This single-centered pilot study . Each patient study approximately 31 week .</brief_summary>
	<brief_title>Beta Blockers Treatment Pulmonary Arterial Hypertension Children</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<criteria>Patients must ≥ 8 ≤ 17.5 year age time study enrollment . Patients must mean pulmonary artery pressure great 25mmHg rest set normal pulmonary arterial wedge pressure 15mmHg less PVR index great 3 Woods units•m2 last hemodynamic study . Patients must diagnose following : Idiopathic PAH ( IPAH ) , PAH associate repaired congenital heart disease , PAH associate minor congenital heart disease ( small interventricular communication , small interarterial communication , small ductus arteriosis ) Patients must clinically stable ( i.e . treatment change ) last 3 month Patients must minimal evidence fluid overload volume depletion judge clinical evaluation ( without diuretic treatment ) Written informed consent Patients unable perform six minute walk test ( 6MWT ) Patients known history pulmonary hypertension secondary venoocclusive disease and/or capillary hemangiomatosis ; pulmonary hypertension owe left heart disease Patients previously receive treatment intravenous positive inotropic agent last 3 month Patients currently receive βblockers Patients know history reactive airway disease ( bronchial asthma relate bronchospastic condition ) Patients chronic obstructive pulmonary disease ( COPD ) Patients known history adverse reaction βblockers Patients heart block ECG rest heart rate &lt; 60 bpm Patients systemic hypotension ( 5th percentile age ) eligible follow : 110 year old : systolic blood pressure define &lt; [ 70 + ( 2 x age year ) ] mmHg ; Older 10 year : systolic blood pressure &lt; 90 mmHg Patients coagulopathy ( INR &lt; 1.5 platelet count &lt; 50,000/mm3 ) Patients known history severe hepatic impairment ( define presence ascites , esophageal varix , jaundice spider angioma ) Patients severe renal insufficiency ( defined creatinine clearance &lt; 30 mL/min/m2 ) Patients known malignancy comorbidity expect limit survival limit ability complete study Patients trisomy 21 Patients know history sick sinus syndrome Patients know history moderate severe primary obstructive valvular heart disease Patients known history diabetes Female patient pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Pulmonary Arterial Hypertension ( PAH</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Right Heart Failure ( RHF )</keyword>
	<keyword>Carvedilol</keyword>
	<keyword>Beta-blockers</keyword>
</DOC>